farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLCfarmaec-54Research ArticleRussian StudiesРоссийские исследованияCLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENTКлинико-экономическая оценка применения карбапенемов (меропенем, имипенем, дорипенем) в лечении нозокомиальной пневмонииШтейнбергЛ. Л.ShteynbergI. I.ЗыряновС. К.ZyryanovS. K.БелоусовЮ. Б.BelousovYu. B.ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава РФ, МоскваРоссияThe Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, MoscowRussian Federation201422032015711418Copyright © Shteynberg I.I., Zyryanov S.K., Belousov Y.B., 20152015Штейнберг Л.Л., Зырянов С.К., Белоусов Ю.Б.Shteynberg I.I., Zyryanov S.K., Belousov Y.B.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/54

the article presents the results of a retrospective study conducted in the period from 2008 to 2011 in Moscow’s hospitals. The aim of the study was to compare the clinical and pharmacoeconomical efficacy of carbapenems in nosocomial pneumonia treatment. The study included 87 patients divided into 3 groups according to the therapy (imipenem, meropenem, doripenem). There were no statistically significant differences in clinical efficacy of carbapenems. Pharmacoeconomic analysis showed more profitable use of imipenem.

в ретроспективном исследовании в период с 2008 по 2011 г. сравнивали клиническую и фармакоэкомическую эффективность применения карбапенемов в лечении нозокомиальной пневмонии в различных стационарах г. Москвы. В исследование было включено 87 больных, выделено три группы в соответствии с проведенной терапией (имипенем, меропенем, дорипенем). Не было выявлено статистически значимых различий в клинической эффективности карбапенемов. Фармакоэкономически более выгодным оказалось применение имипенема.

нозокомиальная пневмониякарбапенемымеропенемимипенемдорипенем.nosocomial pneumoniacarbapenemmeropenemimipenemdoripenemReferencesБелоусов Ю.Б., Омельяновский В.В., Белоусов Д.Ю. Фармакоэкономический анализ применения дорипенема в терапии вентилятор-ассоциированной пневмонии в сравнении с меропенемом и имипенемом. Качественная клиническая практика. 2008; 3: 85-89.Belousov Ju.B., Omel'janovskij V.V., Belousov D.Ju.Farmakojekonomicheskij analiz primenenija doripenema v terapii ventiljator-associirovannoj pnevmonii v sravnenii s meropenemom i imipenemom. Kachestvennaja klinicheskaja praktika. 2008; 3: 85-89.Гончаров В.Б., Руднов В.А., Черкасов Г.В. и соавт. Результаты внедрения концепции инфекционной безопасности в ОРИТ нейрохирургического профиля. Интенсивная терапия. 2007; 4: 3-7.Goncharov V.B., Rudnov V.A., Cherkasov G.V. i soavt. Rezul'taty vnedrenija koncepcii infekcionnoj bezopasnosti v ORIT nejrohirurgicheskogo profilja. Intensivnaja terapija. 2007; 4: 3-7.Иванов Д.В., Бунятян Н.Д., Утешев Д.Б., Корсун Л.В. Особенности антибиотикочувствтельности важнейших грамотрицательных возбудителей нозокомиальных инфекций. Вестник Российского государственного медицинского университета. 2009; 2: 26-29.Ivanov D.V., Bunjatjan N.D., Uteshev D.B., Korsun L.V. Osobennosti antibiotikochuvstvtel'nosti vazhnejshih gramotricatel'nyh vozbuditelej nozokomial'nyh infekcij. Vestnik Rossijskogo gosudarstvennogo medicinskogo universiteta. 2009; 2: 26-29.Иванов Д.В., Егоров A.M. Распространение и механизмы резистентности микроорганизмов продуцирующих бета-лактамазы, фенотипирование потенциальных продуцентов АМРС-беталактамаз семейства Enterobacteriaceae и молекулярные механизмы устойчивости к бета-лактамным антибиотикам штаммов Enterobactercloacae, выделенных при внутрибольничных инфекциях. Биомедицинская химия. 2009; 55 (10): 50-60.Ivanov D.V., Egorov A.M. Rasprostranenie i mehanizmy rezistentnosti mikroorganizmov producirujushhih beta-laktamazy, fenotipirovanie potencial'nyh producentov AMRS-beta-laktamaz semejstva Enterobacteriaceae i molekuljarnye mehanizmy ustojchivosti k beta-laktamnym antibiotikam shtammov Enterobacter cloacae, vydelennyh pri vnutribol'nichnyh infekcijah. Biomedicinskaja himija. 2009; 55 (10): 50-60.Решедько Г.К., Рябкова Е.Л., Козлов Р.С. Современные аспекты эпидемиологии, диагностики и лечения нозокомиальной пневмонии. КМАХ. 2008; 10 (2): 93-188.Reshed'ko G.K., Rjabkova E.L., Kozlov R.S. Sovremennye aspekty jepidemiologii, diagnostiki i lechenija nozokomial'noj pnevmonii. KMAH. 2008; 10 (2): 93-188.Стецюк О.У., Андреева И.В. Современные принципы антибактериальной терапии тяжелых и жизнеугрожающих бактериальных инфекций. Фарматека. 2008; 4: 12-17.Stecjuk O.U., Andreeva I.V. Sovremennye principy antibakterial'noj terapii tjazhelyh i zhizneugrozhajushhih bakterial'nyh infekcij. Farmateka. 2008; 4: 12-17.Чучалин А.Г., Гельфанд Б.Р. и соавт. Нозокомиальная пневмония у взрослых. Национальные рекомендации. Вестниканестезиологиииреаниматологии.2009; 5:39-59.Chuchalin A.G., Gel'fand B.R. i soavt. Nozokomial'naja pnevmonija u vzroslyh. Nacional'nye rekomendacii. Vestnik anesteziologii i reanimatologii. 2009; 5: 39-59.Castanheira M., Jones R.N., Livermore D.M. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. J. Diagn. Microbiol. Infect. Dis. 2009; 63(4): 426-433.Castanheira M., Jones R.N., Livermore D.M. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. J. Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 426-433.Chastre J., Wunderink R., Prokocimer P., Lee M., Kaniga K., Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med. 2008. 36(4): 1089-1096.Chastre J., Wunderink R., Prokocimer P., Lee M., Kaniga K., Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med. 2008. 36 (4): 1089-1096.Colardyn F., Faulkner K.L. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J. Antimicrob. Chemother. 1996; 38: 523-537.Colardyn F., Faulkner K.L. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J. Antimicrob. Chemother. 1996; 38: 523-537.Craig W. Pharmacodinamic/pharmacokinetic parameters: rationale for antibacterial dosing in mice and men. Clin. Infect. Dis. 1998; 26: 1-12.Craig W. Pharmacodinamic/pharmacokinetic parameters: rationale for antibacterial dosing in mice and men. Clin. Infect. Dis. 1998; 26: 1-12.Garau J., Blanquer J., Cobo L. et al. Prospective, randomized, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur. J. Clin. Microbiol. Infect. Dis. 1997; 16:789-796.Garau J., Blanquer J., Cobo L. et al. Prospective, randomized, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur. J. Clin. Microbiol. Infect. Dis. 1997; 16:789-796.Jarvis W.R. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect. Control. Hosp. Epidemiol. 1996; 17 (8): 552-557.Jarvis W.R. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect. Control. Hosp. Epidemiol. 1996; 17 (8): 552-557.Joseph J., Rodvold K.A. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin. Pharmacother. 2008; 9(4): 561-575.Joseph J., Rodvold K.A. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin. Pharmacother. 2008; 9 (4): 561-575.Kollef M.H.et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. J. Critical Care. 2012; 16: P. 218.Kollef M.H.et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. J. Critical Care. 2012; 16: P. 218.Kollef MH. Appropriate Empiric Antimicrobial Therapy of Nosocomial Pneumonia: The Role of the Carbapenems. J. Respir. Care. 2004; 49(12): 1530-1541.Kollef MH. Appropriate Empiric Antimicrobial Therapy of Nosocomial Pneumonia: The Role of the Carbapenems. J. Respir. Care. 2004; 49 (12): 1530-1541.Kongnakorn T., Mwamburi M., Merchant S., Akhras K., Caro J.J., Nathwani D. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. J. Curr. Med. Res. Opin. 2010; 26(1): 17-24.Kongnakorn T., Mwamburi M., Merchant S., Akhras K., Caro J.J., Nathwani D. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. J. Curr. Med. Res. Opin. 2010; 26 (1): 17-24.Masterton R.G. et al. Guidelines for the management of hospitalacquired pneumonia in the UK: report of the working party on hospitalacquired pneumonia of the British Society for Antimicrobial Chemotherapy. J. Antimicrob. Chemother. 2008; 62(1): 5-34.Masterton R.G. et al. Guidelines for the management of hospitalacquired pneumonia in the UK: report of the working party on hospitalacquired pneumonia of the British Society for Antimicrobial Chemotherapy. J. Antimicrob. Chemother. 2008; 62 (1): 5-34.McGarry L.J., Merchant S., Nathwani D., Pawar V., Delong K., Thompson D., Akhras K., Ingham M., Weinstein M.C. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J. Med. Econ. 2010; 13(1): P.142.McGarry L.J., Merchant S., Nathwani D., Pawar V., Delong K., Thompson D., Akhras K., Ingham M., Weinstein M.C. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J. Med. Econ. 2010; 13 (1): P. 142.Merchant S., Gast C., Nathwani D., Lee M., Quintana A., Ketter N., Friedland I., Ingham M. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J. Clin. Ther. 2008; 30(4): 717-733.Merchant S., Gast C., Nathwani D., Lee M., Quintana A., Ketter N., Friedland I., Ingham M. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J. Clin. Ther. 2008; 30 (4): 717-733.Niederman M.S., Craven D.E. et al. American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171: 388-416.Niederman M.S., Craven D.E. et al. American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171: 388-416.Nordmann P., Picazo J.J., Mutters R., Korten V., Quintana A., Laeuffer J.M., Seak J.C., Flamm R.K., Morrissey I. Comparative activity of carbapenem testing: the COMPACT study. J. Antimicrob. Chemother. 2011; 66 (5): P. 1070-8.Nordmann P., Picazo J.J., Mutters R., Korten V., Quintana A., Laeuffer J.M., Seak J.C., Flamm R.K., Morrissey I. Comparative activity of carbapenem testing: the COMPACT study. J. Antimicrob. Chemother. 2011; 66 (5): P. 1070-8.

The authors declare that there are no conflicts of interest present.